Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.
Strom
T B
TB
Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts.
Kelley
V R
VR
Murphy
J R
JR
Nichols
J
J
Woodworth
T G
TG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy; D016207:Cytokines / Q000627:therapeutic use*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000502:physiology*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D000922:Immunotoxins; D015375:Receptors, Interleukin-2